Protection of infant mice against pertussis, tuberculosis and influenza by co-administration of nasal pertussis vaccine candidate BPZE1 and BCG.

ingentiumby ingentium

In Tuberculosis Literature.

Publication date: Jul 18, 2025

Protecting neonates at risk of serious pertussis disease or death represents a global emergency. BPZE1 is the most advanced, next-generation pertussis vaccine undergoing clinical evaluation in children and adults. We investigated the feasibility of co-administering BPZE1 and Bacillus Calmette-Guerin (BCG), the most widely used tuberculosis vaccine worldwide. We showed that BPZE1 can be co-administered with BCG without altering its immunogenicity and protective efficacy against B. pertussis in infant mice. Conversely, BCG immunogenicity and protective efficacy against M. tuberculosis are not affected by BPZE1. Both vaccines induce off-target protection against heterologous infections. In this study, we showed that BPZE1 and BCG alone or in combination induced high levels of protection against influenza challenge in infant mice. In contrast to BCG, the off-target properties of BPZE1 were independent of the age of vaccination. Vaccination with BPZE1 might be considered at the same time as BCG, facilitating its effective implementation in the childhood immunization schedule.

Open Access PDF

Concepts Keywords
Childhood Disease
Death Immunology
Mice Preventive medicine
Tuberculosis
Vaccine

Semantics

Type Source Name
disease MESH pertussis
pathway KEGG Pertussis
disease MESH tuberculosis
pathway KEGG Tuberculosis
disease MESH influenza
drug DRUGBANK BCG vaccine
disease MESH death
disease MESH emergency
disease MESH infections
disease IDO infection
disease IDO cell
disease IDO production
disease IDO toxin
disease IDO cytotoxin
disease MESH meningeal tuberculosis
disease IDO bacteria
disease MESH non infectious diseases
disease IDO colony
drug DRUGBANK Dimercaprol
drug DRUGBANK p-Phenylenediamine
drug DRUGBANK Pentaerythritol tetranitrate
disease MESH morbidity
disease MESH weight loss
pathway REACTOME Influenza Infection
disease MESH cytokine storm
disease MESH lung inflammation
disease MESH virus infection
disease IDO blood
disease MESH respiratory infections
disease MESH respiratory diseases
disease IDO innate immune response
disease MESH infection transmission
disease MESH COVID 19 pandemic
disease IDO facility
disease IDO process
disease MESH tetanus
disease MESH diphtheria
disease MESH inflammation
disease IDO pathogen
disease IDO host
disease MESH bacterial pneumonia
drug DRUGBANK Diethylstilbestrol
disease MESH bacterial infection
drug DRUGBANK Sulfasalazine
disease IDO assay
disease MESH measles
pathway KEGG Measles

Original Article

(Visited 4 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *